Form 4/A for OLMA Olema Pharmaceuticals, Inc.
Accepted 2022-09-23 00:00:00 ET · period of report 2022-09-21 · accession 0001415889-22-009915 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2022-09-23 | 2022-09-21 | OLMA | Bohen Sean | Pres AND CEO, Dir | P - Purchase | — | +20.0K | 74.3K | +37% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-21 | P | A | 20,000 | — | 74,279 | D | — | — | (F2) The weighted average purchase price for the transaction reported was $3.16, and the range of prices were between $3.15 and $3.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. (F3) Includes 5 shares acquired under the issuer's Employee Stock Purchase Plan. |